Adenovirus-mediated HCCS1 overexpression elicits a potent antitumor efficacy on human colorectal cancer and hepatoma cells both in vitro and in vivo

Cancer Gene Therapy

Volumn 15, Issue 12, 2008, Pages 808-816

  Gan, Y ^a   Gu, J ^b   Cai, X ^a   Hu, J ^a   Liu, X Y ^b,c   Zhao, X ^a  

^a SHANGHAI CANCER INSTITUTE   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Gene therapy; Hepatocellular carcinoma suppressor 1; Oncolytic adenovirus

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HCCS1 GENE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 56049124317     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.52     Document Type: Article

References (24)

1. Kondoh N, Wakatsuki M, Hada A, Shuda M, Tanaka K, Arai M et al. Genetic and epigenetic events in human hepatocarcinogenesis. Int J Oncol 2001; 18: 1271-1278.
2. Zhao XT, Li J, He Y, Lan F, Fu L, Guo J et al. A novel growth suppressor gene on chromosome 17p13.3 with a high frequency of mutation in human hepatocellular carcinoma. Cancer Res 2001; 61: 7383-7387.
3. Zhao X, He M, Wan D, Ye Y, He Y, Han L et al. The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett 2003; 190: 221-232.
4. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Therapy 2000; 7: 2-8.
5. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist 2002; 7: 46-59.
6. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481-489.
7. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell Res 2006; 16: 25-30.
8. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-7559.
9. Zhao H, Xu Y. Mad-overexpression down regulates the maliganant growth and p53 mediated apoptosis in human hepatocellular carcinoma BEL7404 cells. Cell Res 1999; 9: 51-59.
10. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371-1381.
11. Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531-541.
12. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005; 11: 553-562.
13. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845-858.
14. Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Caner Res 2006; 66: 4291-4298.
15. Qi R, Gu G, Zhang Z, Yang K, Li B, Fan J et al. Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis. Cancer Gene Ther 2007; 14: 82-90.
16. Gan Y, Zhao X, Hu J, Wang Z, Zhao X. HCCS1 overexpression induces apoptosis via cathepsin D and intracellular calcium, and HCCS1 disruption in mice causes placental abnormality. Cell Death Differ 2008 May 30, [E-pub ahead of print; doi:10.1038/cdd.2008.73].
17. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004; 23: 2881-2890.
18. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis 2006; 11: 143-149.
19. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep 1998; 5: 1349-1361.
20. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-135.
21. Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65: 2993-2995.
22. Conibear E, Stevens TH. Vps52p, Vps53p, and Vps54p form a novel multisubunit complex required for protein sorting at the yeast late Golgi. Mol Biol Cell 2000; 11: 305-323.
23. Leiwen H, Meinhold-Heerlein I, Oliveira V, Schwarzenbacher R, Luo G, Wadle A et al. Characterization of the human GARP (Golgi associated retrograde protein) complex. Exp Cell Res 2005; 306: 24-34.
24. Press B, Feng Y, Hoflack B, Wandinger-Ness A. Mutant rab7 causes the accumulation of cathepsin D and cationin-dependent mannose 6-phosphate receptor in an early endocytic compartment. J Cell Biol 1998; 140: 1075-1089.